Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Cash from Investing Activities: 2019-2024

Historic Cash from Investing Activities for Compass Therapeutics (CMPX) over the last 6 years, with Dec 2024 value amounting to $46.8 million.

  • Compass Therapeutics' Cash from Investing Activities fell 427.92% to -$95.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$74.6 million, marking a year-over-year decrease of 297.68%. This contributed to the annual value of $46.8 million for FY2024, which is 73.45% up from last year.
  • As of FY2024, Compass Therapeutics' Cash from Investing Activities stood at $46.8 million, which was up 73.45% from $27.0 million recorded in FY2023.
  • In the past 5 years, Compass Therapeutics' Cash from Investing Activities registered a high of $46.8 million during FY2024, and its lowest value of -$151.2 million during FY2022.
  • Moreover, its 3-year median value for Cash from Investing Activities was $27.0 million (2023), whereas its average is -$25.8 million.
  • As far as peak fluctuations go, Compass Therapeutics' Cash from Investing Activities crashed by 8,442.37% in 2022, and later skyrocketed by 117.83% in 2023.
  • Yearly analysis of 5 years shows Compass Therapeutics' Cash from Investing Activities stood at $38,000 in 2020, then crashed by 4,757.89% to -$1.8 million in 2021, then tumbled by 8,442.37% to -$151.2 million in 2022, then surged by 117.83% to $27.0 million in 2023, then spiked by 73.45% to $46.8 million in 2024.